The purpose of this project is to advance promising cell based and gene based immunotherapy of malignant gliomas from preliminary animal studies to phase I/II clinical trials. We have shown that glioma tumor antigen presentation through subcutaneous vaccination with autologous dendritic cells primed against autologous major histocompatibility complex type I (MHC-I)-associated tumor peptides induces a potent anti-tumor immune response in a murine glioma model. We previously demonstrated that vaccination with tumor cells engineered to secrete granulocyte/macrophage-colony stimulating factor (GM-CSF) elicits a cytotoxic T-cell mediated immune response in murine intracranial glioma and metastasis models. We have implemented these preclinical studies into clinical protocols for patients with glioblastoma multiforme and anaplastic astrocytoma. We are completing a preliminary phase I trial based on a dendritic cell therapeutic strategy. Preliminary results demonstrate that this form of dendritic cell vaccination can induce a cytotoxic T-cell response which targets intracranial tumor cells. Three hypotheses are proposed for investigation: 1) Induction of peripheral antigen presentation will generate tumor specific T-cells. 2) Cytotoxic T-cells will migrate to and kill intracranial glioma cells. 3) Peripheral vaccination will induce clinical responses and extend survival in patients with glioblastoma and anaplastic astrocytoma. Based on our hypotheses, we will carry out two phase I studies of peripheral vaccination against glioma, the first using an alternative form of dendritic cell immunotherapy with an escalated dose of dendritic cells primed with tumor lysate derived peptides. Concurrently, we will initiate a phase I protocol using a vaccine consisting of allogeneic glioma cells mixed with fibroblasts engineered to secrete GM-CSF. In these studies, we propose the following specific aims: 1) to monitor patients for cellular immune responses and 2) to evaluate the safety and the efficacy of these immunologic strategies. A phase II trial will be initiated in year 3 of the training grant based on the phase I studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23NS002232-03
Application #
6529096
Study Section
NST-2 Subcommittee (NST)
Program Officer
Finkelstein, Robert
Project Start
2000-09-30
Project End
2005-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
3
Fiscal Year
2002
Total Cost
$121,689
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Ghods, Ali Jourabchi; Irvin, Dwain; Liu, Gentao et al. (2007) Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645-53
Liu, Gentao; Yuan, Xiangpeng; Zeng, Zhaohui et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67
Hu, Jinwei; Yuan, Xiangpeng; Belladonna, Maria L et al. (2006) Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 66:8887-96
Yuan, Xiangpeng; Hu, Jinwei; Belladonna, Maria L et al. (2006) Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res 66:2630-8
Liu, Gentao; Akasaki, Yasuharu; Khong, Hung T et al. (2005) Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 24:5226-34
Yuan, Xiangpeng; Curtin, James; Xiong, Yizhi et al. (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23:9392-400
Ehtesham, Moneeb; Kabos, Peter; Gutierrez, Mervin A R et al. (2003) Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 26:107-16
Warner, T G; deKremer, R D; Sjoberg, E R et al. (1985) Characterization and analysis of branched-chain N-acetylglucosaminyl oligosaccharides accumulating in Sandhoff disease tissue. Evidence that biantennary bisected oligosaccharide side chains of glycoproteins are abundant substrates for lysosomes. J Biol Chem 260:6194-9